Pull to refresh
Logo
FAA proposes ending special issuance for non-insulin diabetes pilots

FAA proposes ending special issuance for non-insulin diabetes pilots

Rule Changes

Proposal removes 1959-era barrier for pilots on non-insulin diabetes drugs

Yesterday: FAA publishes proposed rule to remove NIDDM from special issuance

Overview

Updated 1 hour ago

The Federal Aviation Administration proposed a rule on September 4 that would let pilots with non-insulin dependent diabetes get medical certificates from examiners at the time of their exam, instead of waiting months for FAA headquarters review. The regulatory language requiring that review dates to 1959.

The proposal removes "or any other hypoglycemic drug" from the medical standards for first-, second-, and third-class airman certificates. Pilots who use insulin to manage diabetes still face the special issuance requirement, and examiners can defer higher-risk cases to FAA medical staff. The FAA estimates 3,000 applicants a year would qualify.

Why it matters

Pilots with non-insulin diabetes could get medical certificates on exam day instead of waiting months, a change first possible since 1959.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

3,000
Annual applicants who could get AME-issued certificates
Estimated cases per year that would bypass the special issuance process under the proposed rule.
$39.7M–$80.2M
Estimated 5-year industry cost savings
Low and high case labor-hour savings scenarios over five years, before discounting.
67
Years the current regulatory language has stood
Adopted in 1959, the rule has not been updated despite major advances in diabetes treatment.
1,200
Special issuance cases that would transition to AME handling
Existing NIDDM cases currently followed under special issuance that could shift to examiners under the proposal.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 3 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

Organizations Involved

Timeline

January 1959 September 2026

2 events Latest: Yesterday
  1. FAA publishes proposed rule to remove NIDDM from special issuance

    Latest Rulemaking

    Agency proposes deleting "or any other hypoglycemic drug" from part 67 medical standards, letting examiners clear non-insulin diabetes applicants at exam time.

  2. Medical standards adopt hypoglycemic drug disqualification

    Regulation

    FAA adopts rule language treating any diabetes requiring insulin or other hypoglycemic drugs as potentially disqualifying.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

1959

The 1959 medical standard

The FAA adopted regulatory language treating any diabetes requiring insulin or another hypoglycemic drug as potentially disqualifying. At the time, treatment options were limited and the agency had little data on how diabetics performed as pilots.

Then

Diabetics needed individual waivers from FAA medical staff to fly.

Now

Created a 67-year-old framework that medical practice far outpaced. Modern treatments like metformin, GLP-1 agonists, and SGLT2 inhibitors now control most type 2 diabetes without insulin.

Why this matters now

The exact regulatory language from 1959 is what the September 2026 proposal would change.

1995–2013

The diabetes treatment revolution

Metformin became the standard first-line therapy in the mid-1990s, followed by GLP-1 receptor agonists and SGLT2 inhibitors in the 2000s and 2010s. These drugs manage blood glucose effectively without the hypoglycemia risk historically associated with insulin and sulfonylureas.

Then

Most type 2 diabetes patients gained non-insulin options with better safety profiles.

Now

Diabetes-related cardiovascular events and severe hypoglycemia declined, changing the risk calculus for pilot certification.

Why this matters now

The FAA cites these treatment improvements as the reason the 1959 rule no longer fits clinical reality.

Sources

(9)